We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
Read MoreHide Full Article
Key Takeaways
Cardinal Health's Pharmaceutical & Specialty revenues rose 19% to about $61B in Q3 fiscal 2026.
CAH said specialty revenues grew more than 20%, with fiscal 2026 specialty sales seen above $50B.
Cardinal Health highlighted oncology growth above 30% and deeper specialty ecosystem integration.
Cardinal Health’s (CAH - Free Report) Pharmaceutical & Specialty Solutions segment continues to be the primary engine of enterprise growth, delivering another standout quarter in the third quarter of fiscal 2026. Segment revenues climbed 19% to approximately $61 billion, while segment profit increased 29%, underscoring the segment’s growing importance to Cardinal Health’s earnings profile. The strength reflects broad-based demand, expanding specialty capabilities and operational leverage across the platform.
The strong performance can be attributed to healthy growth across brand pharmaceuticals, specialty products, and generics, demonstrating the breadth of Cardinal Health’s pharmaceutical distribution model. Management highlights continued strong pharmaceutical demand across categories, with specialty and branded products making particularly strong contributions to profit growth. Generics also remains a positive contributor, supported by stable market dynamics and the company’s Red Oak sourcing partnership.
Specialty remains the most important structural growth driver. Cardinal Health reported more than 20% specialty revenue growth in the third quarter and reiterated expectations for specialty revenues to exceed $50 billion in fiscal 2026, reflecting momentum across both upstream manufacturer partnerships and downstream provider networks. Demand trends remain especially strong in oncology, urology, and other specialty therapies, supported by physician engagement through Specialty Alliance MSOs and expanding biopharma solutions capabilities.
The company is also deepening integration across its specialty ecosystem. The ongoing onboarding of Solaris and GI Alliance distribution volumes, alongside tuck-in acquisitions within Specialty Alliance, is expanding physician reach and reinforcing cross-platform synergies. Management emphasized that oncology alone continued to grow more than 30%, highlighting robust patient demand and increasing market penetration.
Looking ahead, sustainability appears favorable. Positive demographic trends, increasing specialty drug utilization and deeper manufacturer partnerships continue to support demand. While mix shifts and IRA pricing changes may create revenue volatility, Cardinal Health’s strong profit growth suggests the segment’s momentum remains fundamentally intact.
Peer Updates
The rising demand for specialty solutions, along with attractive margins, has also led the other two leading pharmaceutical distributors — McKesson (MCK - Free Report) and Cencora (COR - Free Report) — to expand into this space.
McKesson continues to deepen its specialty strategy as a key earnings driver, particularly through its oncology and multispecialty platforms. It reported strong revenue and double-digit EPS growth in the fourth quarter of fiscal 2026, supported by strong demand across oncology services, biopharma solutions and pharmaceutical distribution.
MCK highlighted that its oncology network now includes about 3,400 providers, reflecting the expanding scale of its specialty ecosystem. The company is also integrating assets, such as Florida Cancer Specialists and PRISM Vision, strengthening provider services and specialty drug distribution.
With specialty distribution volumes and provider solutions driving operating profit growth, McKesson’s oncology and multispecialty platform is emerging as a key contributor to its long-term earnings expansion.
Cencora is similarly leaning into specialty pharmaceuticals and MSO expansion to accelerate earnings growth. COR reported 6% adjusted operating income growth and 7.5% adjusted EPS growth in the quarter, driven largely by its U.S. Healthcare Solutions segment and specialty drug demand.
The company recently expanded its MSO footprint through the acquisition of OneOncology, complementing Retina Consultants of America and strengthening its specialty ecosystem. Cencora expects these physician-focused platforms to deepen relationships with biopharma companies and specialty providers.
As specialty innovation and complex therapies grow, Cencora believes these MSO partnerships will enhance distribution volumes, support physicians and create new earnings growth opportunities for it.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have lost 11.2% so far this year compared with the industry’s 12.6% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 15.5, above the industry average. It is also higher than its five-year median of 13.65. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
Key Takeaways
Cardinal Health’s (CAH - Free Report) Pharmaceutical & Specialty Solutions segment continues to be the primary engine of enterprise growth, delivering another standout quarter in the third quarter of fiscal 2026. Segment revenues climbed 19% to approximately $61 billion, while segment profit increased 29%, underscoring the segment’s growing importance to Cardinal Health’s earnings profile. The strength reflects broad-based demand, expanding specialty capabilities and operational leverage across the platform.
The strong performance can be attributed to healthy growth across brand pharmaceuticals, specialty products, and generics, demonstrating the breadth of Cardinal Health’s pharmaceutical distribution model. Management highlights continued strong pharmaceutical demand across categories, with specialty and branded products making particularly strong contributions to profit growth. Generics also remains a positive contributor, supported by stable market dynamics and the company’s Red Oak sourcing partnership.
Specialty remains the most important structural growth driver. Cardinal Health reported more than 20% specialty revenue growth in the third quarter and reiterated expectations for specialty revenues to exceed $50 billion in fiscal 2026, reflecting momentum across both upstream manufacturer partnerships and downstream provider networks. Demand trends remain especially strong in oncology, urology, and other specialty therapies, supported by physician engagement through Specialty Alliance MSOs and expanding biopharma solutions capabilities.
The company is also deepening integration across its specialty ecosystem. The ongoing onboarding of Solaris and GI Alliance distribution volumes, alongside tuck-in acquisitions within Specialty Alliance, is expanding physician reach and reinforcing cross-platform synergies. Management emphasized that oncology alone continued to grow more than 30%, highlighting robust patient demand and increasing market penetration.
Looking ahead, sustainability appears favorable. Positive demographic trends, increasing specialty drug utilization and deeper manufacturer partnerships continue to support demand. While mix shifts and IRA pricing changes may create revenue volatility, Cardinal Health’s strong profit growth suggests the segment’s momentum remains fundamentally intact.
Peer Updates
The rising demand for specialty solutions, along with attractive margins, has also led the other two leading pharmaceutical distributors — McKesson (MCK - Free Report) and Cencora (COR - Free Report) — to expand into this space.
McKesson continues to deepen its specialty strategy as a key earnings driver, particularly through its oncology and multispecialty platforms. It reported strong revenue and double-digit EPS growth in the fourth quarter of fiscal 2026, supported by strong demand across oncology services, biopharma solutions and pharmaceutical distribution.
MCK highlighted that its oncology network now includes about 3,400 providers, reflecting the expanding scale of its specialty ecosystem. The company is also integrating assets, such as Florida Cancer Specialists and PRISM Vision, strengthening provider services and specialty drug distribution.
With specialty distribution volumes and provider solutions driving operating profit growth, McKesson’s oncology and multispecialty platform is emerging as a key contributor to its long-term earnings expansion.
Cencora is similarly leaning into specialty pharmaceuticals and MSO expansion to accelerate earnings growth. COR reported 6% adjusted operating income growth and 7.5% adjusted EPS growth in the quarter, driven largely by its U.S. Healthcare Solutions segment and specialty drug demand.
The company recently expanded its MSO footprint through the acquisition of OneOncology, complementing Retina Consultants of America and strengthening its specialty ecosystem. Cencora expects these physician-focused platforms to deepen relationships with biopharma companies and specialty providers.
As specialty innovation and complex therapies grow, Cencora believes these MSO partnerships will enhance distribution volumes, support physicians and create new earnings growth opportunities for it.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have lost 11.2% so far this year compared with the industry’s 12.6% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 15.5, above the industry average. It is also higher than its five-year median of 13.65. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.